Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016

  • ID: 3641103
  • Company Profile
  • 42 pages
  • Global Markets Direct
1 of 4
Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

‘Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Immunomic Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomic Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Immunomic Therapeutics, Inc.
- The report provides overview of Immunomic Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Immunomic Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Immunomic Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Immunomic Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Immunomic Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immunomic Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Immunomic Therapeutics, Inc. Snapshot

Immunomic Therapeutics, Inc. Overview

Key Information

Key Facts

Immunomic Therapeutics, Inc. - Research and Development Overview

Key Therapeutic Areas

Immunomic Therapeutics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Immunomic Therapeutics, Inc. - Pipeline Products Glance

Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Immunomic Therapeutics, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Immunomic Therapeutics, Inc. - Drug Profiles

TriMix-DC

Product Description

Mechanism of Action

R&D Progress

anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine

Product Description

Mechanism of Action

R&D Progress

ASP-4070

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for HIV

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target EGFRvIII for Glioblastoma Multiforme

Product Description

Mechanism of Action

R&D Progress

MC-LAMP-Vax

Product Description

Mechanism of Action

R&D Progress

pp65 DC + Td

Product Description

Mechanism of Action

R&D Progress

ARA-LAMP-Vax

Product Description

Mechanism of Action

R&D Progress

HIV-LAMP-Vax

Product Description

Mechanism of Action

R&D Progress

TN-LAMP-vax

Product Description

Mechanism of Action

R&D Progress

Antigen mRNA Vaccine + LAMP

Product Description

Mechanism of Action

R&D Progress

JCC-LAMP-Vax

Product Description

Mechanism of Action

R&D Progress

Multi-LAMP-Vax

Product Description

Mechanism of Action

R&D Progress

Immunomic Therapeutics, Inc. - Pipeline Analysis

Immunomic Therapeutics, Inc. - Pipeline Products by Target

Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration

Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type

Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action

Immunomic Therapeutics, Inc. - Recent Pipeline Updates

Immunomic Therapeutics, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Immunomic Therapeutics, Inc., Key Information

Immunomic Therapeutics, Inc., Key Facts

Immunomic Therapeutics, Inc. - Pipeline by Indication, 2016

Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016

Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016

Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Immunomic Therapeutics, Inc. - Phase II, 2016

Immunomic Therapeutics, Inc. - Phase I, 2016

Immunomic Therapeutics, Inc. - Preclinical, 2016

Immunomic Therapeutics, Inc. - Discovery, 2016

Immunomic Therapeutics, Inc. - Pipeline by Target, 2016

Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016

Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016

Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2016

Immunomic Therapeutics, Inc., Other Locations

List of Figures

Immunomic Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016

Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016

Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016

Immunomic Therapeutics, Inc. - Pipeline by Top 10 Target, 2016

Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll